文献速递其他结缔组织病

利妥昔单抗治疗系统性硬化症的安全性和有效性(DESIRES):双盲、研究者发起的随机安慰剂对照试验的开放标签扩展期

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Rheumatol · 2022-06-28

DESIRES双盲2期试验显示利妥昔单抗改善系统性硬化症皮肤增厚,本文报告后续24周开放标签扩展期结果。双盲期56例患者随机分配至利妥昔单抗(n=28)或安慰剂(n=28),扩展期中两组均接受利妥昔单抗375 mg/m2静脉给药、每周一次连续4周。利妥昔单抗-利妥昔单抗组mRSS从基线至第24周改善(-5.81 [SD 3.16]),第48周进一步改善(-8.88 [3.10]);安慰剂-利妥昔单抗组第24周mRSS恶化(2.14 [SD 5.51]),第48周改善(-6.05 [4.43])。作者结论认为两疗程利妥昔单抗是安全的,可提供至少48周的持续改善。

要点

  • 利妥昔单抗-利妥昔单抗组mRSS从基线至第48周改善-8.88(SD 3.10)。
  • 安慰剂-利妥昔单抗组第24周mRSS恶化2.14(SD 5.51),第48周改善-6.05(SD 4.43)。
  • 开放标签期每组各1例发生1次严重不良事件(分别为胆管炎和肺炎链球菌性肺炎),随访期间无死亡。

核心结论

  • 两疗程利妥昔单抗是安全的治疗,可为系统性硬化症提供至少48周的持续改善。

研究设计与样本

  • DESIRES试验为研究者发起的2期双盲随机安慰剂对照试验,在日本的四个中心开展。
  • 纳入年龄20-79岁、符合2013年美国风湿病学会和欧洲抗风湿病联盟分类标准、基线改良Rodnan皮肤评分(mRSS)≥10的系统性硬化症患者。
  • 双盲期治疗24周后,两组患者均进入开放标签扩展期,再接受24周利妥昔单抗375 mg/m2静脉给药、每周一次连续4周。
  • 双盲期主要终点为第24周mRSS,在开放标签扩展期第48周重新评估;所有终点均为探索性。
  • 安全性分析纳入所有至少接受一剂研究药物的参与者;有效性分析纳入至少接受一剂且在双盲期第24周和扩展期第48周进行有效性评估者。

主要发现

  • 2017年11月28日至2018年11月6日期间,56例患者被随机分配至利妥昔单抗(n=28)或安慰剂(n=28)。
  • 初始分配至利妥昔单抗的26例和分配至安慰剂的20例转入开放标签扩展期,均至少接受一剂利妥昔单抗;利妥昔单抗-利妥昔单抗组24例和安慰剂-利妥昔单抗组19例完成扩展期。
  • 利妥昔单抗-利妥昔单抗组mRSS从基线至第24周改善-5.81(SD 3.16),第48周进一步改善-8.88(SD 3.10)。
  • 安慰剂-利妥昔单抗组第24周mRSS恶化2.14(SD 5.51),第48周评估时改善-6.05(SD 4.43)。
  • 开放标签期利妥昔单抗-利妥昔单抗组和安慰剂-利妥昔单抗组各1例分别发生1次严重不良事件(胆管炎和肺炎链球菌性肺炎);随访期间无死亡。

关键数值与推荐

  • 纳入标准:符合2013年美国风湿病学会和欧洲抗风湿病联盟分类标准、基线mRSS≥10、年龄20-79岁的系统性硬化症患者。
  • 利妥昔单抗给药方案:375 mg/m2静脉给药,每周一次连续4周。
  • 双盲期主要终点为第24周mRSS,开放标签扩展期第48周重新评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results from the double-blind phase 2 DESIRES trial showed that rituximab improves skin thickening in systemic sclerosis. Here, we present the findings of a subsequent 24-week open-label extension phase. METHODS: Patients with systemic sclerosis aged 20-79 years, who fulfilled the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria, with a baseline modified Rodnan Skin Score (mRSS) of 10 or greater were enrolled into the DESIRES trial, which was an investigator-initiated, phase 2, double-blind, randomised controlled trial of rituximab versus placebo conducted at four sites in Japan. After completion of 24 weeks of treatment with either rituximab or placebo, patients in both groups received a further 24 weeks of rituximab (375 mg/m2 intravenously, once per week for 4 consecutive weeks) in an open-label extension. The primary endpoint of the double-blind trial was mRSS at week 24, which was reassessed at week 48 in the open-label extension. All endpoints were exploratory. Safety analyses included all participants who received at least one dose of study drug; efficacy analyses included those who had received at least one dose and undergone efficacy assessment at 24 weeks in the double-blind phase and at 48 weeks in the extension phase. The DESIRES study is registered with ClinicalTrials.gov, NCT04274257, and UMIN-CTR, UMIN000030139. FINDINGS: Between Nov 28, 2017, and Nov 6, 2018, 56 patients were randomly assigned to either rituximab (n=28) or placebo (n=28) in a double-blind study. 26 patients initially assigned to rituximab and 20 assigned to placebo transitioned to the open-label extension and all received at least one dose of rituximab; 24 participants in the rituximab-rituximab group and 19 in the placebo-rituximab group completed the extension phase. In the rituximab-rituximab group, there was an improvement in mRSS from baseline at week 24 (-5·81 [SD 3·16]), with further improvement at week 48 (-8·88 [3·10]). In the placebo-rituximab group, mRSS worsened at week 24 (2·14 [SD 5·51]) but improved at the week 48 assessment (-6·05 [4·43]). One patient each in the rituximab-rituximab and placebo-rituximab groups experienced one serious adverse event during the open-label phase (cholangitis and pneumococcal pneumonia, respectively). There were no deaths during follow-up. INTERPRETATION: Two courses of rituximab is a safe treatment that can provide sustained improvement in systemic sclerosis for at least 48 weeks. FUNDING: Japan Agency for Medical Research and Development. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2022. PMID: 38294008. doi:10.1016/S2665-9913(22)00131-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。